Company Highlights - The stock of Pag Pharmaceutical-B (02565) rose over 15% at its peak and is currently up 6.29%, trading at HKD 56.65 with a transaction volume of HKD 9.9416 million [1] - Pag Pharmaceutical announced a licensing agreement with PDC FZ-LLC for the exclusive development, distribution, marketing, and commercialization of its core product Visepegenatide (PB-119) in the Middle East and Africa [1] - Visepegenatide (PB-119) is a self-developed GLP-1 receptor agonist designed for weekly subcutaneous injection, aimed at treating type 2 diabetes and weight management [1] - The company believes that this collaboration will leverage PDC's local advantages to expedite the development, registration, and commercialization of Visepegenatide (PB-119) in the targeted regions, creating long-term value and hope for global metabolic disease patients [1] Industry Insights - According to the International Diabetes Federation (IDF), the diabetes prevalence rate among adults in the Middle East and North Africa is 16.2%, the highest globally [2] - The digestive and metabolic drug market, which includes diabetes treatment medications, is the largest therapeutic area in the region, accounting for 20.4% of the market share, with a significant growth of 22.1% expected in Q1 2025 [2] - The global weight management drug market has grown from USD 99.7 billion in 2020 to an estimated USD 112.8 billion by 2024, with a compound annual growth rate (CAGR) of 3.1%, projected to reach USD 277.4 billion by 2034 [2] - The demand for weight management drugs in the Middle East and Africa is expected to be the highest globally, potentially reaching a scale of USD 10 billion by 2034 [2]
派格生物医药-B最高涨超15% GLP-1减重药出海中东及非洲